Full Press Release Details
WATERTOWN, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced that the Company will participate in fireside chats at the following upcoming investor events:
Guggenheim Inaugural Healthcare Innovation Conference in Boston, MA on November 12 at 10:00 a.m. ET;
J.P. Morgan Equity Opportunities Forum in Miami, FL on November 14, one-on-one meetings only;
Stifel 2024 Healthcare Conference in New York, NY on November 18 at 11:30 a.m. ET;
6th Annual Wolfe Research Healthcare Conference in New York, NY on November 19 at 9:20 a.m. ET; and
Jefferies London Healthcare Conference in London, UK on November 20 at 4:00 p.m. GMT.
Live webcasts of the presentations will be available under “News and Events” in the Investors section of the Company’s website at www.kymeratx.com. Replays of the webcasts will be archived and available following the events.
About Kymera Therapeutics
Investor and Media Contact:
Vice President, Investor Relations
Tags
Targeted Protein Degradation